文献速递肝病消化道肿瘤与早癌

MAN2A1-FER融合基因在人类肝脏及其他肿瘤类型中表达,并在小鼠中具有致癌活性

MAN2A1-FER Fusion Gene Is Expressed by Human Liver and Other Tumor Types and Has Oncogenic Activity in Mice.
PubMed 文献 · Gastroenterology · 2017-02-27

该研究检测了多种人类肿瘤和细胞系中MAN2A1-FER融合基因的表达,发现该融合基因在肝癌等多种肿瘤中表达而正常组织中不表达,可激活EGFR下游信号,促进细胞增殖、侵袭和转移,并在小鼠中诱导肝癌发生。

要点

  • MAN2A1-FER融合mRNA和蛋白在肝癌、食管腺癌、胶质母细胞瘤、前列腺癌、非小细胞肺癌和卵巢癌中检出,正常前列腺和肝脏未检出。
  • MAN2A1-FER酪氨酸激酶活性约为野生型FER的4倍,可磷酸化EGFR第88位酪氨酸。
  • 表达MAN2A1-FER的细胞系增殖、克隆形成和侵袭能力增强,小鼠异种移植瘤更大(>2倍)且转移更多。

核心结论

  • 多种人类肿瘤和癌细胞系表达MAN2A1-FER融合基因,该融合基因增加癌细胞增殖和侵袭能力,并在小鼠中具有肝脏致癌活性。

研究设计与样本

  • 研究对102例非小细胞肺癌、61例卵巢癌、70例肝癌、156例胶质母细胞瘤、27例食管腺癌和269例前列腺癌样本以及10例非肿瘤肝组织和20例非肿瘤前列腺组织进行了逆转录聚合酶链反应分析,样本采集于匹兹堡大学。
  • 研究还检测了15种人类癌细胞系的表达,并在NIH3T3、HEP3B、PC3、DU145、H23、A-172细胞系中过表达MAN2A1-FER,在HUH7细胞中敲除该融合基因。
  • 细胞进行了增殖和侵袭实验,并注射到重症联合免疫缺陷小鼠侧腹以评估异种移植瘤生长和转移;肝PTEN缺失小鼠接受尾静脉注射MAN2A1-FER。

主要发现

  • 在肝癌细胞系HUH7以及肝癌、食管腺癌、胶质母细胞瘤、前列腺癌、非小细胞肺癌和卵巢癌中检测到MAN2A1-FER信使RNA和融合蛋白(114 kD),但在非肿瘤前列腺或肝组织中未检测到。
  • MAN2A1-FER蛋白保留了来自MAN2A1的高尔基体定位信号肽,在癌细胞系中从细胞质转位至高尔基体。
  • MAN2A1-FER酪氨酸激酶活性几乎比野生型FER高4倍,并磷酸化表皮生长因子受体N端第88位酪氨酸。
  • 4种细胞系中MAN2A1-FER表达导致表皮生长因子受体激活BRAF、MEK和AKT;HUH7细胞中MAN2A1-FER敲除后这些蛋白磷酸化显著降低。
  • 表达MAN2A1-FER的细胞系增殖、克隆形成和侵袭性增加,小鼠中形成的异种移植瘤更大(>2倍)且转移更多;HUH7细胞敲除MAN2A1-FER后形成的异种移植瘤更小、转移更少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Human tumors and liver cancer cell lines express the product of a fusion between the first 13 exons in the mannosidase α class 2A member 1 gene (MAN2A1) and the last 6 exons in the FER tyrosine kinase gene (FER), called MAN2A1-FER. We investigated whether MAN2A1-FER is expressed by human liver tumors and its role in liver carcinogenesis. METHODS: We performed reverse transcription polymerase chain reaction analyses of 102 non-small cell lung tumors, 61 ovarian tumors, 70 liver tumors, 156 glioblastoma multiform samples, 27 esophageal adenocarcinomas, and 269 prostate cancer samples, as well as 10 nontumor liver tissues and 20 nontumor prostate tissues, collected at the University of Pittsburgh. We also measured expression by 15 human cancer cell lines. We expressed a tagged form of MAN2A1-FER in NIH3T3 and HEP3B (liver cancer) cells; Golgi were isolated for analysis. MAN2A1-FER was also overexpressed in PC3 or DU145 (prostate cancer), NIH3T3 (fibroblast), H23 (lung cancer), and A-172 (glioblastoma multiforme) cell lines and knocked out in HUH7 (liver cancer) cells. Cells were analyzed for proliferation and in invasion assays, and/or injected into flanks of severe combined immunodeficient mice; xenograft tumor growth and metastasis were assessed. Mice with hepatic deletion of PTEN were given tail-vein injections of MAN2A1-FER. RESULTS: We detected MAN2A1-FER messenger RNA and fusion protein (114 kD) in the hepatocellular carcinoma cell line HUH7, as well as in liver tumors, esophageal adenocarcinoma, glioblastoma multiforme, prostate tumors, non-small cell lung tumors, and ovarian tumors, but not nontumor prostate or liver tissues. MAN2A1-FER protein retained the signal peptide for Golgi localization from MAN2A1 and translocated from the cytoplasm to Golgi in cancer cell lines. MAN2A1-FER had tyrosine kinase activity almost 4-fold higher than that of wild-type FER, and phosphorylated the epidermal growth factor receptor at tyrosine 88 in its N-terminus. Expression of MAN2A1-FER in 4 cell lines led to epidermal growth factor receptor activation of BRAF, MEK, and AKT; HUH7 cells with MAN2A1-FER knockout had significant decreases in phosphorylation of these proteins. Cell lines that expressed MAN2A1-FER had increased proliferation, colony formation, and invasiveness and formed larger (>2-fold) xenograft tumors in mice, with more metastases, than cells not expressing the fusion protein. HUH7 cells with MAN2A1-FER knockout formed smaller xenograft tumors, with fewer metastases, than control HUH7 cells. HUH7, A-172, and PC3 cells that expressed MAN2A1-FER were about 2-fold more sensitive to the FER kinase inhibitor crizotinib and the epidermal growth factor receptor kinase inhibitor canertinib; these drugs slowed growth of xenograft tumors from MAN2A1-FER cells and prevented their metastasis in mice. Hydrodynamic tail-vein injection of MAN2A1-FER resulted in rapid development of liver cancer in mice with hepatic disruption of Pten. CONCLUSIONS: Many human tumor types and cancer cell lines express the MAN2A1-FER fusion, which increases proliferation and invasiveness of cancer cell lines and has liver oncogenic activity in mice.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Chen ZH, Yu YP, Tao J, et al. MAN2A1-FER Fusion Gene Is Expressed by Human Liver and Other Tumor Types and Has Oncogenic Activity in Mice. Gastroenterology. 2017. PMID: 28245430. doi:10.1053/j.gastro.2016.12.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。